INVO Fertility will present and host investor meetings at the virtual Lytham Partners Fall 2026 Investor Conference on September 29-30.
Quiver AI Summary
INVO Fertility, Inc., a healthcare company focused on fertility services, will participate in the Lytham Partners Fall 2026 Investor Conference on September 29-30, 2026, via webcast and virtual one-on-one meetings with investors. The webcast presentation is scheduled for September 29 at 11:30 a.m. ET, and it can be accessed through the conference website or a direct link provided in the release. INVO Fertility specializes in expanding access to assisted reproductive technology by establishing and acquiring fertility clinics, currently operating four clinics in the U.S. and offering services such as in vitro fertilization and the innovative INVOcell device. Interested parties can contact Lytham Partners to arrange meetings with the company's management.
Potential Positives
- Participation in a prominent investor conference highlights the company's commitment to engaging with investors and enhancing visibility in the financial market.
- Hosting one-on-one meetings with investors provides an opportunity for management to build relationships and discuss strategic direction, which can boost investor confidence.
- The emphasis on expanding access to assisted reproductive technology demonstrates a strong commitment to addressing patient needs in a growing healthcare sector.
- INVOcell, described as a proprietary and revolutionary medical device, positions the company as an innovator in the fertility space, potentially attracting interest from investors and partners.
Potential Negatives
- Company does not provide specific information on recent financial performance or operational challenges, which may raise concerns among investors about its financial health and growth prospects.
- The press release focuses on an upcoming investor conference but lacks details on current company achievements or strategic initiatives, potentially implying a lack of significant recent progress.
- Limited operational scale with only four clinics may lead to skepticism regarding the company's ability to compete effectively in the broader fertility services market.
FAQ
When is INVO Fertility's webcast presentation scheduled?
The webcast presentation is scheduled for 11:30 a.m. ET on Tuesday, September 29, 2026.
How can I access the INVO Fertility webcast?
The webcast can be accessed via the conference website or directly at https://app.webinar.net/Yy1V3pgKbZQ.
What is the focus of INVO Fertility?
INVO Fertility focuses on expanding access to assisted reproductive technology (ART) care through fertility clinics and related businesses.
How can I arrange a one-on-one meeting with INVO Fertility management?
You can arrange a meeting by contacting Lytham Partners at [email protected].
What innovative technology does INVO Fertility offer?
INVO Fertility offers INVOcell, a proprietary device that allows fertilization and early embryo development in the woman's body.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IVF Revenue
$IVF had revenues of $2.2M in Q2 2026. This is an increase of 16.73% from the same period in the prior year.
You can track IVF financials on Quiver Quantitative's IVF stock page.
You can access data on IVF stock through the Quiver Quantitative API.
$IVF Hedge Fund Activity
We have seen 8 institutional investors add shares of $IVF stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARINER, LLC removed 100,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $190,000
- ARMISTICE CAPITAL, LLC removed 71,866 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $136,545
- VIRTU FINANCIAL LLC added 63,174 shares (+inf%) to their portfolio in Q2 2026, for an estimated $120,030
- SCIENTECH RESEARCH LLC added 32,338 shares (+inf%) to their portfolio in Q2 2026, for an estimated $61,442
- ADAR1 CAPITAL MANAGEMENT, LLC removed 26,722 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $72,683
- GEODE CAPITAL MANAGEMENT, LLC removed 16,848 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $32,011
- STONEX GROUP INC. added 15,702 shares (+inf%) to their portfolio in Q2 2026, for an estimated $29,833
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
SARASOTA, Fla., Sept. 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.
Company Webcast
The webcast presentation will take place at 11:30 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/Yy1V3pgKbZQ . The webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [email protected] or register for the event at https://lythampartners.com/fall2026invreg/ .
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology ("ART") care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on U.S.-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization ("IVF") and the intravaginal culture ("IVC") procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. For more information, please visit invofertility.com .
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
[email protected]
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
[email protected]
